NCT02612454 · Interventional trial
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
Overall registry status Completed
Phase 3
Conditions Atopic Dermatitis
Delaware Valley sites
- Regeneron Investigational site · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory